Ionis Pharmaceuticals: A Pivotal Year of Clinical and Commercial Catalysts

The investment spotlight is firmly on Ionis Pharmaceuticals as the company approaches what could be a transformative period. Beyond the imminent release of quarterly financials, the biotech firm's dense clinical pipeline is set to deliver a series of critical milestones throughout the year, potentially marking its evolution into a fully integrated commercial entity.

The core narrative for Ionis in the coming months revolves around clinical execution and regulatory progress. The company has charted an ambitious course with five major Phase 3 clinical trial readouts scheduled. Concurrently, it plans to submit four New Drug Applications (NDAs), aiming to convert its pioneering RNA-targeting technology into approved therapies.

Central to its commercial strategy are the planned launches of two drugs: Olezarsen for severe hypertriglyceridemia and Zilganersen for Alexander disease. These introductions represent a strategic shift, signaling Ionis's move beyond a research-focused model toward establishing its own commercial footprint.

Key Partnered Programs and Data Catalysts

A significant portion of the upcoming clinical news flow stems from Ionis's collaborative ventures. The first major catalyst is expected this quarter, with results from the Phase 3 study of Bepirovirsen, a potential treatment for chronic hepatitis B developed in partnership with GSK. Positive data would pave the way for a near-term regulatory filing.

Should investors sell immediately? Or is it worth buying Ionis?

Later in the year, attention will turn to the CARDIO-TTRansform trial for Eplontersen. This candidate, advanced with AstraZeneca, targets transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Further pipeline momentum may come from partnered programs with Roche and Otsuka, which are investigating treatments for IgA nephropathy and ALS, respectively.

Financial Foundation and Forthcoming Reports

Providing the backdrop for these clinical endeavors are the company's financial results. Market observers anticipate the release of Ionis's Q4 and full-year 2025 earnings between February 18 and February 25. These figures will offer crucial insight into the company's financial health as it funds its extensive clinical and commercial operations.

The convergence of these events—multiple Phase 3 data readouts, regulatory submissions, and product launches—defines 2026 as a decisive year. The success of this pipeline offensive will largely determine whether Ionis can achieve its growth objectives and solidify its position as a leader in RNA-based therapeutics. The journey begins with the first-quarter data for Bepirovirsen.